# Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

> **NCT01939054** · PHASE2 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** docetaxel
- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT01939054
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2015-09
- **Final completion:** 2016-09
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2015-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01939054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01939054, "Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01939054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*